Tips and Tricks for Diagnosing and Treating Tuberculosis

Similar documents
TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

Diagnosis and Treatment of Tuberculosis, 2011

Tuberculosis Intensive

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Diagnosis of tuberculosis in children

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012

Anti Tuberculosis Medications: Side Effects & adverse Events

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

My heart is racing. Managing Complex Cases. Case 1. Case 1

Ken Jost, BA, has the following disclosures to make:

TB Intensive San Antonio, Texas August 7-10, 2012

New Standards for an Old Disease:

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

Property of Presenter. Not for Reproduction DENVER TB COURSE: CHALLENGING CLINICAL PRESENTATIONS

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Rehuka Khurana, MD, MPH has the following disclosures to make:

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Tuberculosis: A Provider s Guide to

The Next 65 years: TB Technology and Innovation. Bob Belknap M.D. Director, Denver Metro TB Program

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline

Extra pulmonary Tuberculosis

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Extrapulmonary Tuberculosis

TB Intensive Houston, Texas October 15-17, 2013

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Tuberculosis Tools: A Clinical Update

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

Extrapulmonary Tuberculosis XPTB

TB Laboratory for Nurses

Standard TB Treatment

LTBI in Special Populations John Nava, MD October 5, 2010

Treatment of Active Tuberculosis

Tuberculosis and cancer

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

Extrapulmonary Tuberculosis

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects

Case 1: Clinical Presentation

The Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

SA TB Guidelines The interface with Advanced Clinical Care

has the following disclosures to make:

The Lancet Infectious Diseases

Diagnosis and Medical Management of Latent TB Infection

TUBERCULOSIS. Pathogenesis and Transmission

At the end of this session, participants will be able to:

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Treatment of Tuberculosis

Pediatric Tuberculosis

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Tuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED

TB Classification (ATS/CDC)

TB Update: March 2012

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Clinical Presenation & Diagnosis of Tuberculosis Disease

Diagnosing TB in HIV Co- infected PaAents

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center

Annual Tuberculosis Report Oregon 2007

TB 101 Disease, Clinical Assessment and Lab Testing

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Screening and Treatment Recommendations for Persons Exposed to MDR TB

TB Intensive San Antonio, Texas November 11 14, 2014

TB in Corrections Phoenix, Arizona

Tuberculosis in the Traveler

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Diagnosis of tuberculosis in children H Simon Schaaf

Errors in Dx and Rx of TB

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

TB in the Correctional Setting Florence, Arizona October 7, 2014

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

TB Intensive San Antonio, Texas May 7-10, 2013

TB in the Patient with HIV

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Utilizing All the Tools in the TB Toolbox

Interpretation of TST & IGRA results. Objectives

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

TB: A Supplement to GP CLINICS

The Epidemiology of Tuberculosis in Minnesota,

Treatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Treatment of Tuberculosis

TB Nurse Case Management

Transcription:

Tips and Tricks for Diagnosing and Treating Tuberculosis Bob Belknap M.D. Director, Denver Metro TB Program December 6, 2017 DenverPublicHealth.org @DenverPublicHealth @DenPublicHealth

Disclosures No conflicts of interest NAAT off label for non-pulmonary specimens

36 y/o male Fever & abdominal pain x months Born in Cuba PMHx: schizophrenia SocHx: homeless

36 y/o male 6 weeks

36 y/o male

36 y/o male Which test is the most sensitive for diagnosing TB in this patient? 1. Tuberculin skin test (TST) 2. Interferon-gamma release assay 3. AFB smear from a bronchoscopy 4. Nucleic acid amplification test on sputum

Be able to describe: Objectives: 1. the role of AFB smears, cultures and nucleic acid amplification tests 2. the performance of indirect tests for active TB (TST, IGRAs, ADA, and IFN-γ levels) 3. the management of some common problems with TB medications

Born in the Pacific Islands travel in the U.S. military 1 month of cough, fever, weight loss Refused admission 52 y/o male

Hospitalized 2 weeks later QuantiFERON negative Lung bx shows granulomas, AFB smear (-) 52 y/o male Presumed to have hypersensitivity pneumonitis or sarcoidosis

Clinically worse after 1 month on steroids Died shortly after readmission 52 y/o male What went wrong?

2017 New Guidelines Lewinsohn CID 2017: 64 (15 January)

7 Essential Lab Tests for Active TB TEST Time Required 1. Nucleic Acid Amplification for detection 1 d 2. Nucleic Acid Amplification for resistance 1-2 d 3. AFB smear microscopy 1 d 4. Culture (liquid and solid) 10-14d 3-4 wk 5. Identification by probe or HPLC 1d 6. First-line drug susceptibility 1-2 wk 7. Second-line drug susceptibility 3-4 wk Lewinsohn CID 2017: 64 (15 January)

Sensitivity of AFB Smears Respiratory specimens = 30-70% AJIC 2005 33:58; IJTLD 2015 19: 918 Lymphatic TB = 25% CID 2011 53: 555-62 Pleural / peritoneal fluid < 10% J Thorac Dis 2015;7(6):981-991 CSF < 20%, increased with large volume and serial taps British Medical Bulletin, 2015, 113:117 131

Diagnosing Pulmonary TB AFB smears 3 specimens recommended by CDC and NTCA Sensitivity: 70% Specificity: > 90% AFB Cultures: Sensitivity: liquid 88-90% / solid 76% Specificity: > 99% Nucleic Acid Amplification Test (NAAT) recommended on the initial respiratory specimen Lewinsohn CID 2017: 64 (15 January)

GeneXpert for Pulmonary TB Xpert MTB/Rif for Culture confirmed TB in the US Smear AFB (+) 1 Xpert 2 Xpert 2 AFB Smears (n = 91) AFB (+) 68.1% 96.7% 100% AFB (-) 59.3% 71.4% 3 AFB Smears (n = 53) AFB (+) 60.4% 96.8% 100% AFB (-) 57.9% 70% Leutkemeyer CID 2016: 62 (1 May)

GeneXpert for Stopping Airborne Isolation 2 negative GeneXpert to stop isolation Well-collected sputa 5-10 ml (min 3 ml) Not a replacement for culture www.tbcontrollers.org

GeneXpert Omni Small and Portable Durable Low Power Consumption Automatic Connectivity Integrated Battery

Near Future: Xpert - Ultra GeneXpert Imperfect sensitivity in smear (-) disease Detection of silent mutations affecting specificity GeneXpert Ultra Increased volume and optimized chemistry 10 sites /8 countries (Georgia, Belarus, Brazil, Kenya, Uganda, S Africa, India and China) Sensitivity Smear (-)/ Culture (+): Increased 17% HIV-infected patients +12% Rodwell CROI 2017 Oral Abstract

61 y/o female s/p pneumonectomy for granulomatous disease 2 years prior Presented with cough for 1 month, fever and SOB DX: pneumonia and bronchopleural fistula

61 y/o female (-) TST and QFT HD#10 sputum AFB (-) HD#12 BAL AFB (+) Treating physicians believe this is a non-tb mycobacteria (NTM) OK for discharge

Induced sputa vs Bronchoscopy All BAL (+) patients were diagnosed by induced sputa (BAL missed 2) No difference in yield between sputa collected over 3 days vs. 1 day BAL should be limited to patients where other diagnoses are likely or can t induce sputum CID 2007; 44: 1415, IJTLD 2015 19: 918

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRAs) Meta-analysis Data presented for the commercially available assays (QFT-GIT and T-SPOT) Results: % (95% CI) TST 70 (67-72) QFT-GIT 84 (81-87) T-SPOT 88 (85-90) Diel, Chest April 2010 137(4): 952 22

QFT-plus for Active TB Italy 88% (Eur Resp J 2016) Japan 91% (Sci Rep. 2016 Jul 29) 98.9% (J Infect Chemother. 2017 Nov 3) Zambia 83% (Int J Tuberc Lung Dis. 2017 Jun 1)

60 y/o with cryptogenic cirrhosis Jan 2016 - UGIB May 2016 - Sepsis

60 y/o with cryptogenic cirrhosis Pleural fluid RBC 48,000 WBC 1,800 (73% L) Prot 2.2 LDH 279 (serum 422) May 2016 - Sepsis Procalcitonin < 0.05

60 y/o with cryptogenic cirrhosis June July

60 y/o with cryptogenic cirrhosis Pleural fluid ph 7.35 Gluc 138 RBC 46,000 WBC 1,749 (78% L) Prot 2.5 LDH 215 (serum 421) ADA 2.1 Sputum 1+ AFB; GeneXpert (+) TB and Rifampin resistant

ADA and Free IFN-γ Levels Suspected TB Meningitis (1490 suspected / 92 diagnosed) Sens Spec ADA (> 2 U/L) 85.9 77.0 Ekermans BMC ID 2017, 17:104 Meta-analysis Pleural TB (n=1626) Sens Spec ADA 92 90 IFN-γ 89 97 Suspected Pericardial TB (151 suspected / 74 definite /50 probable) Sens Spec ADA (> 35IU/L) 95.7 84.0 IFN-γ (> 44 pg/ml) 95.7 96.3 GeneXpert 63.8 100 Pandie BMC Med 2014, 12:101 Zhou Scientific Reports 2015

ADA and Free IFN-γ Levels Guidelines recommend measuring ADA and IFN-γ levels in fluid when pleural, meningeal, peritoneal, and pericardial TB is suspected Rationale: if sensitivity is > 70% and specificity > 80% then it may be beneficial BUT Lewinsohn CID 2017: 64 (15 January) 1. Generally send-out tests with turn-around times in days 2. Don t replace the need to get tissue cultures for AFB So I think they have a very limited the role in the U.S.

GeneXpert for Extrapulmonary TB WHO - Xpert the preferred initial test for XPTB CDC/ATS/IDSA recommend NAAT testing on XPTB specimens (off label use) Denkinger Eur Resp J 2014 Sensitivity vs Composite Reference GeneXpert Culture Lymph 83 [71-91] 81 [72-88 CSF 81 [59-92] 63 [48-76] Pleural 46 [26-68] 21 [9-34]

29 y/o male with ascites Presents with 2 weeks of fever, chills, nausea and vomiting Originally from Somalia h/o (+) TST and Rx with INH x 9 months

29 y/o male with ascites Peritoneal fluid WBCs 5,904 (71% L) RBCs 4,738; Alb 2.6, LD 195, Prot 5.3 CT with omental thickening Should we get a NAAT on peritoneal fluid?

Diagnosing Extrapulmonary TB AFB Smear (%) AFB Culture (%) Pleural fluid 0-10 23-58 Histology (%) Pleural tissue 14-39 40-85 69-97 Genitourinary Urine Endometrial CSF 10-30 45-70 80-90 86-94 60-70 Peritoneal fluid <5 45-69 79-100 Pericardial fluid 0-42 50-65 73-100 Lewinsohn CID 2017: 64 (15 January)

29 y/o male with ascites Peritoneal biopsy poorly-formed epithelioid granulomas and chronic inflammation with rare possible AFB Side note ADA 4.5 (norm 0-7.3)

Summary 1. the role of AFB smears, cultures and nucleic acid amplification tests AFB smears are not sensitive or specific NAAT testing is recommended in the guidelines fast, accurate, and underutilized AFB culture remains the gold standard Tissue is better than fluid

Summary - Diagnostics 2. the performance of indirect tests for active TB TST, IGRAs, and ADA are not sensitive or specific May have a role as adjuncts when there is diagnostic uncertainty but should not replace biopsies and cultures IFN-γ levels from fluid may be better than ADA but are not yet available

Tuberculosis Treatment Empirical TB treatment Clinical reasons at risk for life-threatening TB, including ones often never confirmed (e.g. < 50% of TB meningitis is culture positive) Public health reasons return to work/school while cultures are pending, children at home, staying in a congregate setting (nursing home or homeless shelter)

23 y/o with lymphadenopathy smear (-), NAAT (+) Started on INH, rifampin, PZA, EMB At 1 month, complaint of losing his hair What is the likely cause? 1. INH 2. Rifampin 3. PZA 4. EMB

Isoniazid (INH) More common Fatigue GI anorexia, nausea, vomiting Hepatitis Maculopapular rash Peripheral neuropathy Sleep hygiene Tip Anti-nausea (ondansetron), anti-anxiety (hydroxyzine) Stop if ALT/AST 3x ULN (>120) with symptoms or > 5x ULN (>200) Treat with topical lotions +/- steroid and anti-histamines Mostly prevented with B6; can be problematic with DM and/or EtOH

Isoniazid (INH) Less common Alopecia Optic neuritis Seizure Vasculitis Anemia Thrombocytopenia Tip Temporary can often continue treatment and reassure Typically think EMB or linezolid Unlikely the sole source, look for other causes (CNS tuberculoma) Stop INH +/- steroids Stop Stop

79 y/o male CC: Cough x 5 months with 20lb wt loss CXR: Large L apical cavity: Sputum: 4+ smear (+) Started on IRZE after 10 days c/o a rash

79 yr old male Platelets 756 LFTs normal

79 yr old male Biopsy - Leukocytoclastic vasculitis Potential causes TB, INH or Rif Treated successfully with Rif, PZA, and EMB

Rifampin (Rif) More common Drug-drug interactions Discoloration of body fluids GI anorexia, nausea, vomiting Maculopapular rash Tip Many are relatively minor (ex. HTN); Important to always review Educate patients to prevent panic see INH see INH

Rifampin (Rif) Less common Hepatitis Hemolytic anemia Management Less than PZA or INH; more often associated with bilirubin Stop Rifampin Thrombocytopenia Stop Rifampin Acute renal failure Stop Rifampin

60 y/o with cryptogenic cirrhosis and rifampin resistant TB

Pyrazinamide (PZA) More common GI anorexia, nausea, vomiting Hepatitis Tip Both are more common with PZA and worse with increasing age Maculopapular rash Arthralgias /myalgias Gout flare see INH Acetaminophen or NSAIDS Anti-inflammatory

60 y/o with cryptogenic cirrhosis Rif-resistant TB Levofloxacin Linezolid EMB Amikacin (TIW) Imipenem

Fluoroquinolones Clearance Prolonged QT - Arrhythmia Tendinitis Tip Moxifloxacin (liver) Levofloxacin (Kidney but not removed by hemodialysis) Moxifloxacin > Levofloxacin Achilles, shoulder, other large joints Hepatotoxicity Maybe Moxifloxacin > Levofloxacin

Fluoroquinolones GI anorexia, nausea, vomiting CNS headache, dizziness, fatigue Tip sometimes improved by switching moxi to levo or levo to moxi Usually can treat symptoms and continue

21 y/o from Micronesia Active TB diagnosed post-partum 1 month reports a mild rash on arm At 2 months it s worse

Questions? DenverPublicHealth.org @DenverPublicHealth @DenPublicHealth